Revolutionary Research Reveals 300 Novel Genetic Connections to Depression

News

Groundbreaking global research has unveiled a deeper insight into depression by discovering nearly 700 genetic variations correlated with the disorder and recognizing more specific and effective treatments.

 

The largest and most varied genetic investigation into depression conducted to date explored the genetic factors behind the disorder and sought to uncover which genes contribute to elevating risk.

 

The research group from Australia and the UK identified 697 variations and 308 genes associated with a heightened risk of depression – a considerable advancement over previous findings.

 

While every genetic variation has a minor effect on the overall likelihood of developing depression, the accumulation of various variants can compound a person’s risk.

 

Dr. Cathy Andronis, Chair of RACGP Specific Interests Psychological Medicine, emphasized to newsGP that it is essential to acknowledge that genetics are not the sole risk contributor and that ‘association does not imply causation’.

 

‘Genetics is akin to the code for our human operating system, and it stands to reason that if we look hard enough, we will identify genes linked to several conditions, including depression,’ she remarked.

 

‘Nevertheless, we are aware that genes manifest as required and can be activated or deactivated based on the environment and the context of a person’s life, meaning each individual will possess a distinct genetic code pattern that can be measured, yet these genes do not singularly cause depression.’

 

The authors of the study emphasize that prior research into the genetics of depression has predominantly focused on white, higher socioeconomic demographics, but this genome-wide association study facilitated the examination of a more diverse group of individuals to identify novel risk factors.

 

A meta-analysis comparing 688,808 individuals with major depression to four million without the disorder across 29 countries, encompassing various ancestries such as East Asian, South Asian, African, and Hispanic, revealed that one in four participants came from a non-European background.

 

Co-author Dr. Brittany Mitchell noted that this diverse sample provided a remarkable enhancement of previously held knowledge and will aid in enhancing outcomes for those battling depression, irrespective of their ethnic background.

 

‘As depression continues to escalate as a major public health challenge, we find ourselves lacking the necessary insights to better treat and prevent it,’ she stated.

 

‘More extensive, inclusive studies such as this one will assist us in developing more effective treatments and interventions, ultimately improving the quality of life and lessening the global consequences of the condition.

 

‘Furthermore, this will reinforce the notion that mental health disorders are as biologically driven as other conditions, such as heart disease.’

 

Dr. Andronis asserts that just like conditions such as heart disease can be prevented and managed, at the core of GPs’ responsibilities in managing depression lies personalized lifestyle recommendations and continual support.

 

‘As GPs, we must guide patients in managing what they can modify, which is almost invariably related to lifestyle,’ she remarked.

 

‘Effective psychotherapy aids patients in recognizing what actions they can undertake to regulate their mood more efficiently. While medication certainly aids some patients at particular times, attention to quality sleep patterns, supportive relationships, nutrition, and physical activity are crucial for everyone, especially for individuals with depression.

 

‘GPs can assist patients by offering psychoeducation and counseling, such as motivational interviewing concerning lifestyle adjustments and enhanced problem-solving skills.’

 

She explains that because depression is a clinical diagnosis, each patient’s symptoms and objectives differ.

 

‘Diagnosing depression involves taking a thorough holistic biopsychosocial history and meticulously crafting a formulation of the patient’s symptoms, risk elements, coexisting conditions, as well as their strengths to collaboratively devise treatment plans tailored to that patient’s requirements,’ she stated.

 

‘We are not machines and therefore cannot be treated with algorithms.’

 

In this study, biological indicators of depression associated with genetics unveiled new pharmaceutical targets and more efficient treatments, indicating potential opportunities for drug repurposing.

 

Over 1600 medications were scrutinized to ascertain their effectiveness on the 308 genes correlated with a higher risk of depression.

 

Although the research team notes that additional studies and clinical trials are necessary, anti-cancer drugs and those utilized for chronic pain and narcolepsy, such as Pregabalin and Modafinil, could potentially be repurposed for the management of depression.

 

Signifying prospects for drug repurposing, the study arrives as innovative treatments for depression surface, comprising psychedelics and ketamine.

 

Depression affects approximately one in five Australians at some point during their lives, a statistic projected to rise over the next ten years, while globally the disorder is expected to affect around 280 million individuals.

 

Dr. Mitchell emphasizes that the ‘landmark study’ is anticipated to serve as a springboard for numerous studies aimed at gaining a better understanding of depression.

 

‘These discoveries signify a substantial advancement in our comprehension of the causes of depression and signal a shift toward more personalized interventions at the appropriate times,’ she asserted.

 

‘The study reveals that there is a robust biological foundation for depression and it’s time we acknowledge it without stigma … treating it with the seriousness it deserves, similar to other medical conditions.’

 

Reiterating calls for a non-stigmatized perspective, Dr. Andronis reflects on a fundamental aspect of being a GP.

 

‘Our humanity and ability to establish trust in a safe doctor-patient relationship is typically among the best forms of treatment for patients,’ she mentioned.

 

Log in below to join the discussion.

antidepressants depression genetics genome-wide association medicine repurposing